Filing Flows › Alkermes (ALKS) › Q1 2026
Alkermes (ALKS) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 5, 2026
Alkermes (ALKS) reported revenue of $393M for the first quarter 2026 (Q1 2026), +28% from a year earlier and +2% from the quarter before. Operating margin was -12.3%, net loss $66.5M (16.9% of revenue).
Alkermes, Q1 2026: revenue $393M (+28% year over year), operating margin -12.3%, net loss $66.5M, operating cash flow −$166M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $393M | +2% | +28% |
| Operating profit | −$48.3M | -183% | -450% |
| Net earnings | −$66.5M | -235% | -396% |
| Operating cash flow | −$166M | -197% | -268% |
What changed
Revenue was $392.9M in Q1 2026, up 28% year over year and up 2% from the previous quarter. Vivitrol was the largest line at 29% of revenue. LYBALVI added $22.3M year over year (up 32%), 26% of the total change. Manufacturing Revenue declined 77%.
Operating costs exceeded revenue by $48.3M, an operating margin of -12.3%. Total costs grew 51% against revenue growth of 28%. The fastest-growing cost line was General & admin (+124%). The quarter ended with a net loss of $66.5M, after a profit of $49.3M the previous quarter.
Operating cash flow was −$165.7M. Non-cash charges added back $19.4M of depreciation and amortization and $36.3M of share-based compensation. Working capital and other items used $155.0M. Capital expenditures of $4.1M exceeded it, leaving free cash flow of −$169.8M.
Questions
What was Alkermes' revenue in the first quarter 2026?
Alkermes (ALKS) reported revenue of $393M for the first quarter 2026 (Q1 2026), +28% from a year earlier and +2% from the quarter before.
Was Alkermes profitable in the first quarter 2026?
Operating loss was $48.3M (-12.3% of revenue) and net loss $66.5M.
Source: Alkermes 10-Q on SEC EDGAR.